[M T]

... plus it hasn’t been shown to prevent a hospitalization. 

If Remdesivir has not yet been studied as a drug given early in the course of the infection (during the viral replication stage, before hospitalization is normally required), that's a shame.  Even if there is a reason the IV can't be given to an outpatient (at a clinic, like blood donation, dialysis, cancer treatments, ...), it would seem that a small study could have been done with hospitalizing some willing, high-risk patients soon after symptom onset and giving them the IVs.  Perhaps there was such a study and I am unaware of it.

If an early course of Remdesivir reduces the virus enough to mostly avoid the immune system kicking into overdrive, and results in less frequent hospitalizations (& ICU & death), imagine what the inhalation form will cost if they price it at the cost of the hospitalization it reduces.

[M T]

... plus it hasn’t been shown to prevent a hospitalization. 

If Remdesivir has not yet been studied as a drug given early in the course of the infection (during the viral replication stage, before hospitalization is normally required), that's a shame.  Even if there is a reason the IV can't be given to an outpatient (at a clinic, like blood donation, dialysis, cancer treatments, ...), it would seem that a small study could have been done with hospitalizing some willing, high-risk patients soon after symptom onset and giving them the IVs.  Perhaps there was such a study and I am unaware of it.

If an early course of Remdesivir reduces the virus enough to mostly avoid the immune system kicking into overdrive, and results in less frequent hospitalizations (& ICU & death), imagine what the inhalation form will cost if they price it at the cost of the hospitalization it reduces.